MedTrace Logo

Single Ascending Dose Study of ATH-097 in Healthy Participants

NCT07640269 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-06-10

No results posted yet for this study

Summary

This is a Phase I, A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ATH-097 in Healthy Participants

Conditions

  • This is a Phase I Study Conducted in Healthy Volunteers

Interventions

DRUG

ATH-097

Oral Suspension, 6 dose levels

DRUG

Placebo

Oral Suspension: Dosing volume identical to the experimental arm

Sponsors & Collaborators

  • Atheron Therapeutics, Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-06
Primary Completion
2026-10-20
Completion
2026-10-20

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07640269 on ClinicalTrials.gov